Savolitinib is an experimental small molecule inhibitor of c-Met.

It is being investigated for the treatment of cancer by AstraZeneca.

[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.

[2] It has been given conditional approval for these indication in China.

[3]